MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Clinical trials for MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted therapy duo takes aim at hard-to-treat blood cancer
Disease control OngoingThis study tests a combination of two drugs—tagraxofusp and decitabine—for people with chronic myelomonocytic leukemia or related high-risk blood disorders. Tagraxofusp delivers a toxin directly to cancer cells, while decitabine is a chemotherapy that stops cancer growth. The goa…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:56 UTC
-
Smart bomb for leukemia: new combo targets tough cancers
Disease control OngoingThis early-phase study tests a new targeted drug (PVEK) combined with standard chemotherapy for adults with aggressive forms of acute myeloid leukemia and related blood cancers. PVEK works like a smart bomb, attaching to cancer cells and delivering chemotherapy directly to them. …
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Could a targeted drug boost chemo for tough blood cancers?
Disease control OngoingThis study tests whether adding the experimental drug veliparib to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. About 25 adults took part. The goal was to see…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New transplant timing strategy may tame High-Risk blood cancers
Disease control OngoingThis study tests a specific schedule of chemotherapy drugs (busulfan and fludarabine) followed by a donor stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. After the transplant, a drug called cyclophosphamide is given to help prevent the don…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New drug combo aims to improve leukemia treatment
Disease control OngoingThis phase 2 trial tests whether adding venetoclax to ASTX727 (a two-drug pill) works better than ASTX727 alone for adults with chronic myelomonocytic leukemia or related bone marrow cancers with excess blasts. About 132 participants will receive either the combination or ASTX727…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
Donor vaccine may shield transplant patients from dangerous virus
Prevention OngoingThis early-phase trial tests whether vaccinating stem cell donors against cytomegalovirus (CMV) can help protect the transplant recipient from CMV infection. About 34 people with blood cancers receiving a donor stem cell transplant will have their donors vaccinated before donatio…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Prevention
Last updated May 06, 2026 16:13 UTC
-
Blood test study seeks hidden enzyme deficiency in cancer patients
Knowledge-focused OngoingThis study looks at how often people with certain blood cancers or related conditions have an acquired form of pyruvate kinase deficiency, a red blood cell enzyme problem. Researchers will take a single blood sample from 100 participants to check enzyme activity and gene changes.…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC